Clinical Trial Update: Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Tagraxofusp (SL-401) in chronic myelomonocytic leukemia and myelofibrosis has completed with results posted (January 2025).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myelomonocytic Leukemia

Drugs mentioned

• Tagraxofusp (SL-401) (tagraxofusp)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-06